These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 17762530)

  • 1. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
    Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
    Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversing anticoagulants both old and new.
    Warkentin TE; Crowther MA
    Can J Anaesth; 2002; 49(6):S11-25. PubMed ID: 12557411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial.
    Kenet G; Stenmo CB; Blemings A; Wegert W; Goudemand J; Krause M; Schramm W; Kirchmaier C; Martinowitz U
    Thromb Haemost; 2010 Feb; 103(2):351-9. PubMed ID: 20024491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants.
    Vavra KA; Lutz MF; Smythe MA
    Ann Pharmacother; 2010 Apr; 44(4):718-26. PubMed ID: 20233918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.
    Desmurs-Clavel H; Huchon C; Chatard B; Negrier C; Dargaud Y
    Thromb Res; 2009 Mar; 123(5):796-8. PubMed ID: 18771795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
    Bijsterveld NR; Moons AH; Boekholdt SM; van Aken BE; Fennema H; Peters RJ; Meijers JC; Büller HR; Levi M
    Circulation; 2002 Nov; 106(20):2550-4. PubMed ID: 12427650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
    Siddiqui F; Tafur A; Bontekoe E; Iqbal O; Jeske W; Mehrotra S; Hoppensteadt D; Ramacciotti E; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029619895120. PubMed ID: 31914798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging anticoagulants: mechanism of action and future potential.
    Klement P; Rak J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
    Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
    Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New parenteral anticoagulants in development.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Rocha E; Pozo-Hernández C; Vargas-Castrillón E
    Ther Adv Cardiovasc Dis; 2011 Feb; 5(1):33-59. PubMed ID: 21045018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay.
    Bourti Y; Fazavana J; Armand M; Saller F; Lasne D; Borgel D; Bianchini EP
    Thromb Haemost; 2016 Aug; 116(3):452-60. PubMed ID: 27412396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux.
    Lisman T; Bijsterveld NR; Adelmeijer J; Meijers JC; Levi M; Nieuwenhuis HK; De Groot PG
    J Thromb Haemost; 2003 Nov; 1(11):2368-73. PubMed ID: 14629471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo reversal of the anticoagulant effects of edoxaban.
    Halim AB; Samama MM; Mendell J
    Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors.
    Taketomi T; Szlam F; Vinten-Johansen J; Levy JH; Tanaka KA
    Blood Coagul Fibrinolysis; 2007 Dec; 18(8):761-7. PubMed ID: 17982317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.
    Godier A; Miclot A; Le Bonniec B; Durand M; Fischer AM; Emmerich J; Marchand-Leroux C; Lecompte T; Samama CM
    Anesthesiology; 2012 Jan; 116(1):94-102. PubMed ID: 22042412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro effect of activated recombinant factor VII (rFVIIa) on coagulation properties of human blood at hypothermic temperatures.
    Kheirabadi BS; Delgado AV; Dubick MA; Scherer MR; Fedyk CG; Holcomb JB; Pusateri AE
    J Trauma; 2007 Nov; 63(5):1079-86. PubMed ID: 17993954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
    Tanaka KA; Szlam F; Sun HY; Taketomi T; Levy JH
    Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
    Gerotziafas GT; Depasse F; Chakroun T; Samama MM; Elalamy I
    Thromb Haemost; 2004 Mar; 91(3):531-7. PubMed ID: 14983229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.